People: Insmed Incorporated (INSM.O)

INSM.O on Consolidated Issue listed on NASDAQ Capital Market

0.81USD
9 Feb 2010
Price Change (% chg)

$0.00 (+0.62%)
Prev Close
$0.81
Open
--
Day's High
$0.83
Day's Low
$0.80
Volume
459,079
Avg. Vol
620,591
52-wk High
$2.57
52-wk Low
$0.41

view people for:

Summary

Name Age Since Current Position
Sharoky, Melvin 58 2009 Chairman of the Board
Tully, Kevin 55 2006 Chief Financial Officer, Executive Vice President
Kelley, Glen 41 2008 Vice President - Regulatory Affairs
Glover, Steve 49 2009 Chief Business Officer
Condon, Kenneth 61 1999 Director
Crooke, Graham 50 1999 Director
Engelsen, Steinar 59 1999 Director
Whitcomb, Randall 54 2001 Director
Lanfear, Dennis 53 2007 Director
» Insider Trading

Biographies

Name Description
Sharoky, Melvin Dr. Melvin Sharoky has been appointed as Chairman of the Board of Insmed Inc effective June 16, 2009. He is a Member of the Board of Insmed Incorporated since May 2001. From January 2002 to March 2007, he was President and CEO of Somerset Pharmaceuticals, Inc., a research and development pharmaceutical company which markets Eldepryl® for the treatment of patients with late stage Parkinson’s disease and developed EMSAM®, which is licensed to Bristol-Myers Squibb, for depressive disorder. Dr. Sharoky continued as a consultant to Somerset until December 2007. He previously served as President of Somerset Pharmaceuticals from July 1995 to June 2001. From June 2001 to January 2002, Dr. Sharoky was retired. From July 1995 through January 1998, Dr. Sharoky was President of Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, and from February 1993 to January 1998 he was also President and CEO of its wholly-owned subsidiary, Circa Pharmaceuticals, Inc., which develops, manufactures and markets solid dosage generic pharmaceutical products to wholesale distributors. Dr. Sharoky joined Circa Pharmaceuticals in July 1988 as Medical Director, served as Senior Vice President and Director of Research and Development from April 1991 to August 1992, and as Executive Vice President and Director of Research and Development from August 1992 to January 1993. Prior to this, from February 1986 to June 1988, he was Vice President and Chief Medical Officer of Pharmakinetics Laboratories, Inc. He is currently a member of the Board of Directors of Par Pharmaceuticals. Dr. Sharoky received a B.A. in biology from the University of Maryland in Baltimore County and an M.D. from the University of Maryland School of Medicine.
Tully, Kevin Mr. Tully returned as the Executive Vice President and Chief Financial Officer in February 2006, after having served as Chief Financial Officer at Bostwick Laboratories, a private pathology laboratory from August 2005 until February 2006. From April 2005 to August 2005, Mr. Tully served as the Chief Financial Officer, Treasurer and Controller. From January 2002 until April 2005, Mr. Tully was the Treasurer, Controller and Principal Financial Officer, and from August 2001 until his election as Treasurer, he served as Senior Director, Finance and Administration. Mr. Tully initially joined the company in March 2001 as Director of Finance and has over 30 years of experience across Europe and the Americas covering the financial, marketing and the manufacturing aspects of business with Tenneco and UCB. Mr. Tully received his Ordinary National Certificate in Business and Administration from St. Helens College in England and is a Certified General Accountant.
Kelley, Glen Mr. Glen Kelley is Vice President of Regulatory Affairs of Insmed Incorporated since February 2008. From April 2001 to December 2006 Mr. Kelley held positions of management in Operations and Intellectual Property for Insmed. Prior to joining Insmed, Mr. Kelley was in the external relations department of drug discovery at R.W Johnson Pharmaceutical Research Institute from 1999 to 2001 and worked in various roles with Ortho Clinical Diagnostics from 1990 to 1999. Mr. Kelley has over 20 years of experience in the biotechnological and pharmaceutical industry. He received his Bachelor of Science degree in Biological Science from Rutgers College and was a Post-Qualifying PhD Candidate in Microbiology and Molecular Genetics at Rutgers University.
Glover, Steve Mr. Glover is Chief Business Officer of Insmed Incorporated. Mr. Glover joined Insmed in June 2007 and served as President of Insmed Therapeutic Proteins from June 2007 until March 2009. After the sale of the follow-on biologics assets to Merck and Co. on March 31, 2009, Mr. Glover became Chief Business Officer. From January 2006, Mr. Glover was President and CEO of ZyVer & Associates, a biopharmaceutical consulting firm, through which he worked as a consultant to on the follow-on biologics program from March 2007 to June 2007. From March 2003 to December 2006, Mr. Glover served as Senior Vice President and General Manager of Andrx Therapeutics and Andrx Laboratories, both divisions of Andrx Corporation. From January 2001 to February 2003, Mr. Glover served as Founder of Triangular Health Inc., a privately held venture funded company. Prior to Triangular Health, he held various executive positions at IMS Health, Amgen and Hoffman LaRoche. Mr. Glover has over 25 years of business experience in bio-pharmaceuticals and life sciences. He received his Bachelor of Science degree in Marketing/Management from Illinois State University.
Condon, Kenneth Mr. Condon has been a Member of the Board since the inception in November 1999 and was a director of Insmed Pharmaceuticals, the predecessor entity, from 1997 to 2000. Since October 2007, Mr. Condon has been employed as the Chief Financial Officer and Assistant Secretary of American International College. He joined Boston University in 1975 and served as its Treasurer and Vice President for Financial Affairs from September 1986 until September 2007. He was also a Trustee of Newbury College. He was formerly Chairman of the Board of BayFunds, a $1.8 billion mutual fund family; a former director of BayBank Harvard Trust; a former member of the BankBoston Advisory Board; a former director of the BayBank Trust Board; a former director of Seragen, Inc., a biotechnology firm; a former director, Chapter Secretary, Treasurer and President of the Financial Executives Institute of Massachusetts; and Director and Treasurer of the Boston Municipal Research Bureau. Before 1975, Mr. Condon was a Senior Accountant with the CPA firm of Arthur Andersen & Co. in Boston. He received his B.A. degree in Economics and Mathematics from Tufts University, and his M.B.A. in finance from the Wharton School of Finance, University of Pennsylvania. Mr. Condon was both a Certified Public Accountant and a Certified Financial Planner.
Crooke, Graham Dr. Crooke has been a Member of the Board since the inception in November 1999 and was a director of Insmed Pharmaceuticals, predecessor entity, from 1996 to 2000. Dr. Crooke has been a partner of Asset Management Company, a venture capital firm focusing on investments in early stage information technology and life sciences companies since April 2000. Previously, from September 1997 through March 2000, Dr. Crooke was a partner at Ticonderoga Capital, a venture capital firm, where he focused on biotechnology and healthcare service investments. From April 1992 until September 1997, Dr. Crooke was an associate, and later a Vice President of Dillon Read Venture Capital, a venture capital firm and predecessor to Ticonderoga. Prior to that, Dr. Crooke worked with the healthcare practice of Booz, Allen & Hamilton, Inc., a management consulting firm, was a product manager at Molecular Devices Corporation, a developer of bioanalytical measurement systems, and, from 1984 to 1986, practiced medicine at teaching hospitals in Western Australia. He received his medical degree from the University of Western Australia and his M.B.A. from Stanford University’s Graduate School of Business.
Engelsen, Steinar Dr. Engelsen has been a member of the Board since the inception in November 1999 and was a Director of Insmed Pharmaceuticals, predecessor entity, from 1998 to 2000. Since November 1996, Dr. Engelsen has been a partner of Teknoinvest Management AS, a venture capital firm based in Norway. In addition, from January to November 2000, Dr. Engelsen was acting Chief Executive Officer of Centaur Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 until October 1996, Dr. Engelsen held various management positions within Hafslund Nycomed AS, a pharmaceutical company based in Europe, and affiliated companies. He was responsible for therapeutic research and development, most recently serving as Senior Vice President, Research and Development of Nycomed Pharma AS from January 1994 until October 1996. Dr. Engelsen received his M.Sc. in nuclear chemistry and his M.D. from the University of Oslo, and is a Certified European Financial Analyst.
Whitcomb, Randall Dr. Whitcomb has been a Member of the Board since November 2001. Since late 2006, Dr. Whitcomb has served as a consultant to several privately held biotechnology companies. He also serves as a Senior Advisor to Frazier Healthcare Ventures, a dedicated healthcare venture capital company. From 2001 to 2006, Dr. Whitcomb served as Chief Medical Officer at, and was a Founder of, Quatrx Pharmaceuticals, Inc., a privately-held, drug development company focusing on discovery, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular areas. From 1992 through 2000, he held various management positions with Parke-Davis Pharmaceutical Research, Inc., a division of Warner Lambert Company, finally serving as Vice President of Drug Development with particular responsibility for the development and approval of products for women’s health care and diabetes. After the merger of Warner Lambert into Pfizer, Inc., Dr. Whitcomb was Vice President, Global Project Management for Pfizer Global Research and Development. From 1987 through 1992 he was on the faculty of the Massachusetts General Hospital and Harvard Medical School. He received his B.A. degree from Tabor College and his M.D. degree from the University of Kansas.
Lanfear, Dennis Mr. Lanfear has been a member of the Board since December 2007. He was a strategic Consultant for the company from 2005 until he was appointed to the Board in December 2007. Since 2005, Mr. Lanfear has been President and CEO of InteKrin Therapeutics, a clinical-stage, privately held biopharmaceutical company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Mr. Lanfear was at Amgen Inc. from 1986 to 1999 where he was a Corporate Officer and Vice President with broad operational, product development and marketing responsibility. He also held senior leadership roles in several product development programs including those for growth factors, somatotrophins and neurotrophins, directing efforts from preclinical to Phase III. In 1997, he was named Vice President, Market Development, where he defined long term competitive and reimbursement strategies for Epogen™, a multibillion dollar anemia drug. Prior to joining Amgen, Mr. Lanfear held positions of increasing responsibility at Baxter International and was also the founder and former CEO of Saronyx, Inc., a drug development software services company. He is also an active life science investor through his firm, Lanfear Capital Advisors, which invests in pharmaceutical and medical device companies. Mr. Lanfear earned bachelor’s degrees in Biochemistry and Chemical Engineering from Michigan State University and earned his M.B.A. from the Anderson School at UCLA.

Basic Compensation

Name Fiscal Year Total
Sharoky, Melvin --
Tully, Kevin 658,436
Kelley, Glen --
Glover, Steve 703,288
Condon, Kenneth --
Crooke, Graham --
Engelsen, Steinar --
Whitcomb, Randall --
Lanfear, Dennis --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Sharoky, Melvin 0 0
Tully, Kevin 143,225 156,125
Kelley, Glen 0 0
Glover, Steve 0 0
Condon, Kenneth 0 0
Crooke, Graham 0 0
Engelsen, Steinar 0 0
Whitcomb, Randall 0 0
Lanfear, Dennis 0 0

Insider Trading

Name Shares Traded Price
LANFEAR DENNIS M 14,620 $0.00
WHITCOMB RANDALL W 14,620 $0.00
CROOKE GRAHAM K 14,620 $0.00
SHAROKY MELVIN 14,620 $0.00
ENGELSEN STEINAR J 14,620 $0.00
CONDON KENNETH G 14,620 $0.00
SHAROKY MELVIN 120,000 $0.00
LANFEAR DENNIS M 120,000 $0.00
ALLAN GEOFFREY Z 531,156 $1.00
FARRAR DOUG 85,966 $0.00
GLOVER STEPHEN C 232,381 $1.00
ENGELSEN STEINAR J 120,000 $0.00
ALLAN GEOFFREY Z 358,707 $1.00
TULLY KEVIN P 111,646 $1.00
GLOVER STEPHEN C 105,049 $1.00
FARRAR DOUG 97,966 $1.00
TULLY KEVIN P 202,872 $1.00
ALLAN GEOFFREY Z 531,156 $0.00
FARRAR DOUG 184,429 $1.00
GLOVER STEPHEN C 232,381 $0.00
CONDON KENNETH G 120,000 $0.00
WHITCOMB RANDALL W 120,000 $0.00
ALLAN GEOFFREY Z 247,582 $0.00
TULLY KEVIN P 94,562 $0.00
GLOVER STEPHEN C 108,317 $0.00
» Full list on Insider Trading
view people for: